Marshall Wace, LLP Rigel Pharmaceuticals Inc Transaction History

Marshall Wace, LLP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.12 - $1.57 $491,189 - $688,542	438,562 New	438,562 $649,000
Q3 2023 Nov 14, 2023	BUY	$1.07 - $1.39 $38,538 - $50,063	36,017 New	36,017 $38,000
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $215,913 - $345,462	172,731 New	172,731 $228,000
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $163,363 - $247,122	-69,222 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $242,277 - $311,499	69,222 New	69,222 $251,000
Q3 2020 Nov 16, 2020	SELL	$1.78 - $4.13 $48,601 - $112,765	-27,304 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$1.41 - $2.05 $38,498 - $55,973	27,304 New	27,304 $50,000
Q4 2019 Feb 14, 2020	SELL	$1.6 - $2.43 $1.13 Million - $1.72 Million	-709,026 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.63 - $2.62 $876,185 - $1.41 Million	-537,537 Reduced 43.12%	709,026 $1.33 Million
Q2 2019 Aug 14, 2019	BUY	$2.02 - $2.61 $202,335 - $261,433	100,166 Added 8.74%	1,246,563 $3.25 Million
Q1 2019 May 14, 2019	BUY	$2.0 - $2.65 $1.62 Million - $2.15 Million	810,228 Added 241.02%	1,146,397 $2.95 Million
Q4 2018 Feb 14, 2019	BUY	$2.08 - $3.36 $421,767 - $681,317	202,773 Added 152.01%	336,169 $773,000
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.59 $284,674 - $393,069	109,490 Added 458.0%	133,396 $428,000
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $67,653 - $98,253	23,906 New	23,906 $68,000

355K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.77B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.